Hepatorenal syndrome

Board exam relevance: in 1 of more than 100 exam reports · rank 181
Synonyms
HRS, HRS-AKI, kidney failure in cirrhosis, liver-related kidney failure
Specialty
Internal medicine · Liver & biliary tract
Last updated
10/2026 · Dr. Pascal Bafteh
Contents
  1. Definition
  2. Classification
  3. Aetiopathogenesis
  4. Clinical features
  5. Diagnosis
  6. Treatment principles
  7. Keep learning in the app
  8. Further reading (open access)
  9. Cross-references

Definition

Hepatorenal syndrome (HRS) is a functional, potentially reversible renal dysfunction in advanced liver cirrhosis with ascites or in alcoholic steatohepatitis. Structural kidney damage is typically absent; the cause is markedly reduced renal perfusion.

Classification

  • HRS type 1 (historical term): rapidly progressive kidney failure; in the classic definition, doubling of serum creatinine to above 2.5 mg/dL within less than two weeks
  • HRS type 2 (historical term): moderate, stable or slowly progressive renal dysfunction with creatinine of 1.5–2.5 mg/dL, often together with ascites that is difficult to control

According to the consensus of the International Club of Ascites (ICA) and ADQI (2024), these terms are replaced by HRS-AKI (acute kidney injury), HRS-AKD (kidney dysfunction for less than 90 days without meeting AKI criteria) and HRS-CKD (more than 90 days).

Aetiopathogenesis

The starting point is arterial splanchnic vasodilatation in portal hypertension. The effective arterial blood volume falls, and the renin-angiotensin-aldosterone system, the sympathetic nervous system and vasopressin (ADH) are activated in response. Sodium and water retention promote ascites and hyponatremia. The result is severe renal vasoconstriction with a fall in glomerular filtration rate.

HRS is frequently triggered by an event that further impairs the circulation, such as a bacterial infection (especially spontaneous bacterial peritonitis), gastrointestinal bleeding or marked fluid loss.

Clinical features

HRS usually occurs in patients with advanced cirrhosis and ascites or with alcoholic hepatitis. It is characterised by increasing oliguria and a rise in nitrogenous waste products without structural kidney damage. Hyponatremia, ascites that is difficult to control and other signs of decompensation are often present.

HRS is a frequent organ manifestation of acute-on-chronic liver failure; kidney failure is the most common form of organ failure in that setting.

Diagnosis

Diagnostic criteria

HRS-AKI is a diagnosis of exclusion. Diagnostic criteria according to the ICA and ADQI consensus (2024):

  • liver cirrhosis with ascites
  • acute kidney injury according to KDIGO: rise in serum creatinine of at least 0.3 mg/dL within 48 hours or of at least 50% from baseline within 7 days and/or urine output of at most 0.5 mL/kg per hour for at least 6 hours
  • no improvement in creatinine and/or urine output within 24 hours after adequate volume expansion, if clinically required
  • no strong evidence of another primary cause of kidney injury, such as septic shock, drug-induced kidney injury, urinary tract obstruction or acute glomerular injury

HRS-AKI may also be present with tubular injury, proteinuria or pre-existing chronic kidney disease. Older criteria, for example those of the 2019 German guideline, instead required serum creatinine above 1.5 mg/dL, no improvement after at least two days of volume expansion with albumin without fluid-removing medicines, and exclusion of shock, nephrotoxic medicines and parenchymal kidney disease (proteinuria above 0.5 g per day, microscopic hematuria with more than 50 red cells per high-power field, abnormal renal ultrasound).

Because many patients with cirrhosis have low muscle mass, creatinine underestimates the loss of renal function; a rapid rise is therefore relevant even below fixed thresholds.

Urine findings and triggers

In addition, a low urinary sodium concentration and a bland urinary sediment support HRS and argue against acute tubular necrosis. Triggers are also sought, in particular spontaneous bacterial peritonitis (diagnostic paracentesis) and gastrointestinal bleeding.

Treatment principles

  • Initial steps are withdrawal of diuretics and nephrotoxic drugs, treatment of precipitants such as infection or bleeding, and correction of hypovolaemia with albumin.
  • In confirmed hepatorenal syndrome, vasoconstrictors combined with albumin are given under close monitoring.
  • The definitive treatment is liver transplantation, and renal replacement therapy can be used as a bridge.

Specific treatment regimens with drugs and doses are covered in the InnereFuchs app.

Keep learning in the app

In the InnereFuchs app you can learn Hepatorenal syndrome with flashcards, exam questions and image tasks (ECG, chest X-ray, ultrasound, lab values) – free, in your browser or as an app.

Open in browser  About InnereFuchs →

Further reading (open access)

  1. AWMF-Leitlinienregister 021-017: Komplikationen der Leberzirrhose (S2k-Leitlinie DGVS, Fassung 2019)
  2. MSD Manual Professional: Systemic Abnormalities in Liver Disease
  3. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting
  4. A Review for the Practicing Clinician: Hepatorenal Syndrome, a Form of Acute Kidney Injury, in Patients with Cirrhosis

Cross-references

Keep learning

Keep learning with flashcards, exam questions and spot diagnoses in the InnereFuchs app – free, in your browser or as an app.

Related pages: Liver cirrhosis · Primary biliary cholangitis (PBC) · Autoimmune hepatitis

Note: Learning content for medical education – not a treatment recommendation and no substitute for diagnosis or treatment decisions in individual cases. Treatment and management are deliberately not covered on this page.